

## Intellectual Property Portfolio Updates

### Key Highlights:

- The US Patent and Trademark Office (USPTO) has granted EBR three new patents
- The Japan Patent Office has granted one new patent
- EBR's Intellectual Property portfolio now includes 58 granted US patents, 9 granted non-US patents and 13 patent applications pending among other IP, with the latest patents expiring in 2043.
- The Company received a preliminary disallowance notice from the USPTO on its application for a patent term extension on one US patent.
- The WiSE® technology is supported by a substantial IP portfolio, with ongoing R&D activities generating new patent applications that, if granted, will extend the system's patent runway.

**Sunnyvale, California; 11 December 2025:** EBR Systems, Inc. (ASX: "EBR", "EBR Systems", or the "Company"), developer of the world's only wireless cardiac pacing device for heart failure, provides an update on its Intellectual Property portfolio with the grant of four additional new patents and the preliminary notice disallowing a patent extension application for one patent.

The USPTO has granted EBR three new patents, while the Japan Patent Office has granted one new patent. This brings EBR's outstanding patents to 58 granted U.S. patents, 9 granted non-U.S. patents, and 13 patent applications.

The patent families cover different aspects of WiSE® including, but not limited to the technological inventions incorporated in:

- leadless cardiac pacing using ultrasound transduction;
- the sensor/transmitter;
- the receiver/stimulator electrode;
- the programmer;
- the delivery system; and
- mechanisms for detecting the location of the receiver/transducer electrode.

EBR's patents provide protection of the technology incorporated in WiSE including some patents with expiry dates out to 2043.

### Patent Term Extension Application

The U.S. has a mechanism, referred to as a Patent Term Extension (PTE), that enables patent holders to extend the period of protection provided by one of their patents to partially compensate for time involved in conducting clinical studies and securing regulatory approval from the FDA. EBR identified a patent that currently expires in the year 2030 and sought to extend that by approximately 4.5 years.

EBR's patent portfolio is managed by an external patent firm. Under US law, a PTE must be submitted within 60 calendar days of FDA approval. The PTE application was lodged by the law firm one day after the statutory 60-day deadline and the USPTO has issued a preliminary notice disallowing the extension. The USPTO is seeking additional information from the FDA prior to a final notice. The Company is currently obtaining independent expert advice regarding its options and available recourse and will update the market as appropriate.

### Continued R&D activities

The WiSE technology is currently protected by a substantial IP portfolio. EBR continues to conduct research and development activities directed at improving the use and performance of the WiSE System. This has and will continue to result in the filing of new patent applications that will provide longer patent runway should they be granted.

EBR has extensive experience with WiSE and the underlying technology for providing leadless cardiac stimulation using ultrasound transduction. This has resulted in extensive know-how and trade secrets that are also likely to represent significant barriers to any emerging competitors considering the development of a similar product. EBR remains unaware of any technologies currently in development that it considers to be a direct competitor.

## ENDS

*This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a committee of the Board of Directors*

### For more information, please contact:

#### Company

Andrew Shute  
Chief Corporate Development Officer  
P: +44 7730 691421  
E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

#### Investor Relations

Gabriella Hold  
The Capital Network  
P: +61 2 8999 3699  
E: [gaby@thecapitalnetwork.com.au](mailto:gaby@thecapitalnetwork.com.au)

### About EBR Systems

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

### EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not

actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

**Foreign Ownership Restriction**

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

For personal use only